-

LivaNova to Host Investor Day on November 12, 2025

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025, beginning at 9 a.m. EST until approximately 1 p.m. EST in New York City and via webcast. Members of the executive leadership team, including Chief Executive Officer Vladimir Makatsaria and Chief Financial Officer Alex Shvartsburg, along with select members of the management team, will present the Company’s strategic roadmap and growth pillars.

In-person attendance requires advance registration. Please contact InvestorRelations@livanova.com for further information.

LivaNova will webcast the event on the Company’s website at www.livanova.com. A replay and presentation materials will be posted immediately following the event in the Investors section of the LivaNova website.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding upcoming events. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts

+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com

Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.25B (2024)
Net Income: $63.2M (2024)

Release Summary
LivaNova PLC announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025.
Release Versions
$Cashtags

Contacts

LivaNova Investor Relations and Media Contacts

+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com

Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

Social Media Profiles
More News From LivaNova PLC

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with an apnea-hypopnea index (AHI) between 15 and 65...

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $360.9 million increased 12.1% on a reported basis and 9.5% on both a constant-currency and organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $0.56 and adjusted diluted earnings per share o...

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to...
Back to Newsroom